Literature DB >> 19889888

Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Margaret C Bell1, Patricia R Robuck, Elizabeth C Wright, Marina S Mihova, Charlotte Hofmann, Jennifer L De Santo, Susan L Milstein, Pamela A Richtmyer, Janel L Shelton, Maureen Cormier, Debra L King, Choon J Park, Wallis A Molchen, Yoon Park, Michelle Kelley.   

Abstract

BACKGROUND: Even though adverse event (AE) collection and official accounting are mandatory for clinical trials, there are limited detailed guidelines specifying how to summarize the event for reporting in a timely and expeditious manner. This article details the AE and serious adverse event (SAE) reporting summary developed for a large multi-center National Institutes of Health (NIH)-sponsored clinical trial.
PURPOSE: To review and analyze the large volume of AE data reported by 10 sites (806 SAEs and 19,034 AEs from August 2000 to May 2007) the automated SAE summary was developed. It was designed to ensure timeliness and clarity in the complex process of AE review and reporting.
METHODS: The AE and SAE case report forms (CRFs) as well as the automated SAE summary were developed within a database management system developed by the Data Coordinating Center (DCC) which allowed for web-based data entry at the DCC and 10 sites and offered immediate overall and site-specific reports accessible by the DCC, site, and NIH project staff.
RESULTS: The automated SAE summary pulled data from multiple CRFs to create a succinct and informative summary and allowed for prompt and easy reporting to the regulatory agencies. The summary was adaptable to the needs of reviewers because of the availability of multiple search options.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889888      PMCID: PMC3753781          DOI: 10.1177/1740774509348525

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  8 in total

1.  Systematic identification and classification of adverse events in human research.

Authors:  David I Silverman; Lisanne Cirullo; Nicholas A DeMartinis; Kathryn Damato; Margaret DeMeo; Gustavo A Fernandez; Laura Glynn; Upendra Hegde; Elizabeth Laskay; Robin Leger; Khamis Abu-Hasaballah; Joan M Caron
Journal:  Contemp Clin Trials       Date:  2006-03-06       Impact factor: 2.226

2.  Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury.

Authors:  Kartik Jinjuvadia; Wendy Kwan; Robert J Fontana
Journal:  Am J Gastroenterol       Date:  2007-07-27       Impact factor: 10.864

3.  Heterogeneous but "standard" coding systems for adverse events: Issues in achieving interoperability between apples and oranges.

Authors:  Rachel L Richesson; Kin Wah Fung; Jeffrey P Krischer
Journal:  Contemp Clin Trials       Date:  2008-03-05       Impact factor: 2.226

4.  A unified web-based query and notification system (QNS) for subject management, adverse events, regulatory, and IRB components of clinical trials.

Authors:  Rick Mitchell; Maitri Shah; Sushma Ahmad; Audrey Smith Rogers; Jonas H Ellenberg
Journal:  Clin Trials       Date:  2005       Impact factor: 2.486

5.  Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project.

Authors:  Stephen R Wisniewski; Heather Eng; Leslie Meloro; Robert Gatt; Louise Ritz; Diane Stegman; Madhukar Trivedi; Melanie M Biggs; Edward Friedman; Kathy Shores-Wilson; Diane Warden; Douglas Bartolowits; Jeffrey P Martin; A John Rush
Journal:  Clin Trials       Date:  2004       Impact factor: 2.486

Review 6.  Patient-reported outcomes and the evolution of adverse event reporting in oncology.

Authors:  Andy Trotti; A Dimitrios Colevas; Ann Setser; Ethan Basch
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

7.  Needles in haystacks.

Authors:  Adrian Reuben
Journal:  Am J Gastroenterol       Date:  2007-11       Impact factor: 10.864

8.  Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

Authors:  William M Lee; Jules L Dienstag; Karen L Lindsay; Anna S Lok; Herbert L Bonkovsky; Mitchell L Shiffman; Gregory T Everson; Adrian M Di Bisceglie; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Elizabeth C Wright; James E Everhart
Journal:  Control Clin Trials       Date:  2004-10
  8 in total
  1 in total

1.  Processes to manage analyses and publications in a phase III multicenter randomized clinical trial.

Authors:  Kristin K Snow; Margaret C Bell; Anne M Stoddard; Teresa M Curto; Elizabeth C Wright; Jules L Dienstag
Journal:  Trials       Date:  2014-05-07       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.